BR9607846A - Inibição da associação de tau-tau - Google Patents
Inibição da associação de tau-tauInfo
- Publication number
- BR9607846A BR9607846A BR9607846A BR9607846A BR9607846A BR 9607846 A BR9607846 A BR 9607846A BR 9607846 A BR9607846 A BR 9607846A BR 9607846 A BR9607846 A BR 9607846A BR 9607846 A BR9607846 A BR 9607846A
- Authority
- BR
- Brazil
- Prior art keywords
- tau
- disease
- present
- pathological
- association
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001575 pathological effect Effects 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000026072 Motor neurone disease Diseases 0.000 abstract 1
- 102000008763 Neurofilament Proteins Human genes 0.000 abstract 1
- 108010088373 Neurofilament Proteins Proteins 0.000 abstract 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 230000003436 cytoskeletal effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 210000005044 neurofilament Anatomy 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9506197.4A GB9506197D0 (en) | 1995-03-27 | 1995-03-27 | Inhibition of tau-tau association. |
| PCT/EP1996/001307 WO1996030766A1 (en) | 1995-03-27 | 1996-03-25 | Inhibition of tau-tau-association |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9607846A true BR9607846A (pt) | 1998-07-14 |
| BR9607846B1 BR9607846B1 (pt) | 2009-05-05 |
Family
ID=10771951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9607846-4A BR9607846B1 (pt) | 1995-03-27 | 1996-03-25 | métodos de seleção de agentes que modulam ou inibem associação de tau-tau, ou revertem toxicidade na célula de tau agregado. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US6376205B1 (pt) |
| EP (2) | EP0817969B1 (pt) |
| JP (1) | JP3612078B2 (pt) |
| CN (3) | CN100406892C (pt) |
| AT (2) | ATE221662T1 (pt) |
| AU (1) | AU5334496A (pt) |
| BR (1) | BR9607846B1 (pt) |
| CA (2) | CA2633573C (pt) |
| DE (2) | DE69638197D1 (pt) |
| DK (2) | DK1067386T3 (pt) |
| ES (2) | ES2180753T3 (pt) |
| GB (1) | GB9506197D0 (pt) |
| HK (1) | HK1068950A1 (pt) |
| MX (1) | MX9706902A (pt) |
| PT (2) | PT1067386E (pt) |
| TR (1) | TR199701039T1 (pt) |
| WO (1) | WO1996030766A1 (pt) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| WO1999011814A1 (en) * | 1997-09-04 | 1999-03-11 | Board Of Trustees Of Leland Stanford Jr. University | Assays for detecting modulators of cytoskeletal function |
| US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
| CN1100787C (zh) * | 1998-05-08 | 2003-02-05 | 北京大学 | 新型血吸虫疫苗肽 |
| CA2384006A1 (en) * | 1999-09-09 | 2001-03-15 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | A minimal tau peptide for the nucleation of paired helical filaments |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| GB0100119D0 (en) * | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| AU2007200212B2 (en) * | 2001-01-15 | 2010-08-26 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0113121D0 (en) | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
| GB0117326D0 (en) * | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US20050079526A1 (en) * | 2002-02-20 | 2005-04-14 | Affinium Pharmaceuticals, Inc. | Methods and apparatuses for characterizing refolding and aggregation of biological molecules |
| US7794965B2 (en) * | 2002-03-13 | 2010-09-14 | Signum Biosciences, Inc. | Method of identifying modulators of PP2A methylase |
| DK1521831T3 (da) * | 2002-07-12 | 2008-06-30 | Axon Neuroscience | Transgent dyr der udtrykker trunkeret alzheimers tauprotein |
| US7172875B2 (en) * | 2003-02-18 | 2007-02-06 | The Ohio State University Research Foundation | Identifying inhibitors of intracellular protein fibrillization |
| CA2535873A1 (en) * | 2003-08-18 | 2005-02-24 | Novartis Ag | 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof |
| WO2005080986A1 (en) * | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| EP3564223A1 (en) * | 2004-09-23 | 2019-11-06 | WisTa Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1843734A4 (en) * | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
| US20060188866A1 (en) * | 2005-02-18 | 2006-08-24 | Children's Hospital Oakland Research Institute | Diaminophenothiazine compositions and uses thereof |
| EP2013191B3 (en) * | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| AU2013200732B2 (en) * | 2006-03-29 | 2015-04-09 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
| EP2853293B1 (en) * | 2006-03-29 | 2017-11-22 | WisTa Laboratories Ltd. | Thioninium compounds and their use |
| PT2004155T (pt) | 2006-03-29 | 2018-05-02 | Wista Lab Ltd | Inibidores de agregação proteica |
| HUE030621T2 (en) | 2006-07-11 | 2017-05-29 | Wista Lab Ltd | Methods for the synthesis and / or purification of diaminophenothiazinium compounds |
| WO2008121412A1 (en) * | 2007-03-30 | 2008-10-09 | The Regents Of The University Of California | Proanthocyanidins from cinnamon and its water soluble extract inhibit tau aggregation |
| CN101820884B (zh) | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| SI2205245T1 (sl) * | 2007-10-03 | 2015-10-30 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
| EP2090166A1 (de) * | 2008-02-14 | 2009-08-19 | Bayer CropScience AG | Flüssige herbizide Zubereitungen |
| EP2272955B1 (en) | 2008-04-09 | 2015-08-26 | Tokyo Metropolitan Institute of Medical Science | Tdp-43-storing cell model |
| ES2600278T3 (es) | 2008-12-10 | 2017-02-08 | Wista Laboratories Ltd. | Sales de xantilio 3,6-disustituidas como medicamentos |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| PL2430007T3 (pl) | 2009-05-12 | 2014-07-31 | Wista Lab Ltd | Sposoby chemicznej syntezy związków diaminofenotiazyniowych z zastosowaniem nadsiarczanowych środków utleniających |
| WO2011017319A1 (en) | 2009-08-03 | 2011-02-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein polymerization |
| WO2011036558A2 (en) | 2009-09-24 | 2011-03-31 | Wista Laboratories Ltd. | Crystalline methylthionium chloride (methylene blue) hydrates |
| CN102549438B (zh) * | 2009-09-24 | 2014-10-29 | 国家健康与医学研究院 | Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍 |
| WO2011056222A1 (en) * | 2009-11-05 | 2011-05-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein aggregation |
| US8809617B2 (en) | 2009-11-05 | 2014-08-19 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Automated high-content live animal drug screening using C. elegans |
| US9072772B2 (en) | 2009-11-05 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating disorders associated with protein aggregation |
| US8796448B1 (en) * | 2010-12-09 | 2014-08-05 | Prosetta Antiviral Inc. | Compounds, compositions, and methods for treating Alzheimer's disease |
| EP2645994B1 (en) | 2010-11-30 | 2017-11-01 | WisTa Laboratories Ltd. | Formulations comprising methylthioninium chloride |
| DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
| CA2826286C (en) * | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| US9283230B2 (en) | 2011-02-11 | 2016-03-15 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
| US8349376B1 (en) * | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
| US9506051B2 (en) * | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| WO2012166862A1 (en) | 2011-06-01 | 2012-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods for treating alzheimer's disease |
| GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| UA115657C2 (uk) | 2011-09-19 | 2017-12-11 | Аксон Ньюросайєнс Сє | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла |
| EP2834270B1 (en) | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| RU2661111C2 (ru) | 2013-03-15 | 2018-07-11 | Ац Иммуне С.А. | Антитела к тау и способы применения |
| GB201317702D0 (en) | 2013-10-07 | 2013-11-20 | Wista Lab Ltd | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| US10765755B1 (en) | 2013-11-20 | 2020-09-08 | University Of South Florida | Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies |
| JP6370674B2 (ja) * | 2014-10-22 | 2018-08-08 | 国立研究開発法人国立長寿医療研究センター | タウオパチー治療薬およびそのスクリーニング方法 |
| EP3253875B1 (en) * | 2015-02-04 | 2020-01-08 | H. Hoffnabb-La Roche Ag | Tau antisense oligomers and uses thereof |
| KR101722930B1 (ko) * | 2015-06-19 | 2017-04-04 | 한국과학기술연구원 | 전이성 타우 단백질 및 이의 제조 방법 |
| GB201512678D0 (en) | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| EP4223297A3 (en) | 2016-07-25 | 2023-11-15 | WisTa Laboratories Ltd. | Administration and dosage of diaminophenothiazines |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| CN111094327A (zh) * | 2017-08-16 | 2020-05-01 | Lgv1有限公司 | Bpifb4蛋白的用于神经元疾病和损伤的vtft同种型 |
| BR112021000802A2 (pt) | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| CN113874078A (zh) | 2019-04-05 | 2021-12-31 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
| GB202010620D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | System |
| GB202010652D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| GB202213796D0 (en) | 2022-09-21 | 2022-11-02 | Wista Lab Ltd | Tau aggregation inhibitors |
| WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US391675A (en) * | 1888-10-23 | Rack for exhibiting hose or other goods | ||
| BE569430A (pt) * | 1957-07-17 | |||
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| JPH0833127B2 (ja) * | 1990-05-01 | 1996-03-29 | 株式会社ユニシアジェックス | 内燃機関の空燃比制御装置 |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| JP3210336B2 (ja) | 1991-07-10 | 2001-09-17 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | フルオロケミカル撥水性および撥油性処理組成物 |
| EP0600951A4 (en) * | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
| WO1993003177A1 (en) * | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Novel tau/neurofilament protein kinases |
| ES2136654T3 (es) * | 1991-12-06 | 1999-12-01 | Max Planck Gesellschaft | Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer. |
| GB9316727D0 (en) * | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| AU708682B2 (en) | 1994-08-08 | 1999-08-12 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US6953675B2 (en) * | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
| WO1999062548A1 (en) | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Methods and compositions for diagnosing tauopathies |
| FR2788436A1 (fr) | 1999-01-14 | 2000-07-21 | Pf Medicament | Composition d'un derive de phenothiazine |
| WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| US7838107B2 (en) | 2004-09-14 | 2010-11-23 | Denki Kagaku Kogyo Kabushiki Kaisha | Aluminum-silicon carbide composite |
| EP3564223A1 (en) | 2004-09-23 | 2019-11-06 | WisTa Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
-
1995
- 1995-03-27 GB GBGB9506197.4A patent/GB9506197D0/en active Pending
-
1996
- 1996-03-25 AT AT96910015T patent/ATE221662T1/de active
- 1996-03-25 CN CN2004100317408A patent/CN100406892C/zh not_active Expired - Lifetime
- 1996-03-25 DK DK00121739.7T patent/DK1067386T3/da active
- 1996-03-25 PT PT00121739T patent/PT1067386E/pt unknown
- 1996-03-25 BR BRPI9607846-4A patent/BR9607846B1/pt not_active IP Right Cessation
- 1996-03-25 DE DE69638197T patent/DE69638197D1/de not_active Expired - Lifetime
- 1996-03-25 CN CNB961928700A patent/CN1150404C/zh not_active Expired - Lifetime
- 1996-03-25 DK DK96910015T patent/DK0817969T3/da active
- 1996-03-25 EP EP96910015A patent/EP0817969B1/en not_active Expired - Lifetime
- 1996-03-25 TR TR97/01039T patent/TR199701039T1/xx unknown
- 1996-03-25 CA CA2633573A patent/CA2633573C/en not_active Expired - Lifetime
- 1996-03-25 WO PCT/EP1996/001307 patent/WO1996030766A1/en active IP Right Grant
- 1996-03-25 EP EP00121739A patent/EP1067386B1/en not_active Expired - Lifetime
- 1996-03-25 PT PT96910015T patent/PT817969E/pt unknown
- 1996-03-25 ES ES96910015T patent/ES2180753T3/es not_active Expired - Lifetime
- 1996-03-25 ES ES00121739T patent/ES2346284T3/es not_active Expired - Lifetime
- 1996-03-25 US US08/913,915 patent/US6376205B1/en not_active Expired - Lifetime
- 1996-03-25 AT AT00121739T patent/ATE470860T1/de active
- 1996-03-25 CN CNA2006101006617A patent/CN1935143A/zh active Pending
- 1996-03-25 MX MX9706902A patent/MX9706902A/es active IP Right Grant
- 1996-03-25 JP JP52891696A patent/JP3612078B2/ja not_active Expired - Lifetime
- 1996-03-25 DE DE69622701T patent/DE69622701T2/de not_active Expired - Lifetime
- 1996-03-25 CA CA002215397A patent/CA2215397C/en not_active Expired - Lifetime
- 1996-03-25 AU AU53344/96A patent/AU5334496A/en not_active Abandoned
-
2002
- 2002-03-28 US US10/107,181 patent/US6953794B2/en not_active Expired - Fee Related
-
2005
- 2005-02-15 HK HK05101186A patent/HK1068950A1/xx not_active IP Right Cessation
- 2005-07-07 US US11/175,153 patent/US20060014216A1/en not_active Abandoned
-
2006
- 2006-12-11 US US11/636,628 patent/US8278298B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/979,252 patent/US7534786B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9607846A (pt) | Inibição da associação de tau-tau | |
| DK0484281T3 (pt) | ||
| TW264480B (pt) | ||
| ZA977310B (en) | Transdermal propentofylline compositions for the treatment of Alzheimer's disease. | |
| PL322333A1 (en) | Dna encoding human papilloma viruses of type 18 | |
| DE69735417D1 (de) | 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen | |
| AU634003B2 (en) | 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants | |
| FR2786099B1 (fr) | Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline | |
| DE69822628D1 (de) | Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate | |
| IT1264562B1 (it) | Composizione farmaceutica per l'applicazione topica di 17,b estradiolo nel trattamento della cheratocongiuntivite sicca | |
| FI101548B1 (fi) | Menetelmä ja laite karheemisessa | |
| ES2127133A1 (es) | Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer. | |
| DE29621667U1 (de) | Mittel zur Entlastung des menschlichen Körpers von Schwermetallen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer |
Free format text: THE UIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) |
|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: WISTA LABORATORIES LTD. (SG) Free format text: TRANSFERIDO DE: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI-52400.061589/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132279-24.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: WARSAW ORTHOPEDIC, WISTA LABORATORIES, WYETH, WYETH HOLDINGS CORPORATION. |
|
| B21B | Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties |
Free format text: SOLICITADA ATRAVES DA PETICAO 860130005431, DE 23/10/2013 |